Sulfamonomethoxine sodium

Synonyms: 磺胺间甲氧嘧啶钠盐
Sulfamonomethoxine sodium 是一种具有口服活性的广谱合成磺胺类抗生素 (antibiotic),通过抑制二氢蝶酸合成酶发挥作用,可升高血糖水平、诱导焦虑相关行为并损害空间学习与记忆能力,可用于焦虑症、空间记忆障碍、大肠杆菌败血症、沙门氏菌病及葡萄球菌感染的相关研究。
产品编号: MS-Y43697 纯度: 99.88% CAS No.: 38006-08-5 分子式: C11H11N4NaO3S 分子量: 302.29
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
100mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
询价
5g
询价
询价
(0.1 - 0.2mg)
询价
询价

产品描述

Sulfamonomethoxine sodium 是一种具有口服活性的广谱合成磺胺类抗生素 (antibiotic),通过抑制二氢蝶酸合成酶发挥作用,可升高血糖水平、诱导焦虑相关行为并损害空间学习与记忆能力,可用于焦虑症、空间记忆障碍、大肠杆菌败血症、沙门氏菌病及葡萄球菌感染的相关研究。

生物实验数据

生物活性 Sulfamonomethoxine sodium is an orally active broad-spectrum synthetic sulfonamide antibiotic (antibiotic) that inhibits dihydropteroate synthase, elevates blood glucose levels, induces anxiety-related behaviors, and impairs spatial learning and memory, and it is used in research on anxiety disorders, spatial memory impairment, Escherichia coli septicemia, salmonellosis, and staphylococcal infections.
IC50 & Target

IC50: antibacterial

体内研究
(In Vivo)

Sulfamonomethoxine sodium (10-200 mg/kg/day;口服给药;每日一次,共 18 天) 在妊娠期的母体暴露会导致子代小鼠出现剂量依赖性、性别特异性的生理变化。
Sulfamonomethoxine sodium (43.6-65.5 mg/kg;口服给药;每日 1 次,持续 7 天) 可导致产蛋母鸡的鸡蛋中残留物长期滞留,给药后 2 天达到最高浓度。

Animal Model: ICR (female)
Dosage: 10 mg/kg/day; 50 mg/kg/day; 200 mg/kg/day
Administration: p.o.; daily; GD 1-18
Result: Increased blood glucose levels in both male (p < 0.05) and female (p < 0.01) offspring at PND 22 with 200 mg/kg/day exposure.
Reduced kidney coefficients in male offspring (p < 0.05) at PND 22 with 200 mg/kg/day exposure.
Reduced serum BH4 levels to 5.7 pg/mL (p < 0.05) and BDNF levels to 162.5 pg/mL (p < 0.01) in male offspring at PND 22 with 200 mg/kg/day exposure.
Reduced body weight in male offspring at PND 35 (p < 0.05) with 10 mg/kg/day exposure compared to controls.
Reduced body weight in female offspring at PND 28 (p < 0.01) with 10 mg/kg/day exposure compared to controls.
Reduced total distance traveled (p < 0.05) and number of squares crossed (p < 0.05) in both male and female offspring at PND 50 with 50 mg/kg/day exposure.
Reduced entries into the central area in male offspring (p < 0.05) at PND 50 with 50 mg/kg/day exposure.
Reduced entries into the central area (p < 0.05) and time spent in the central area (p < 0.05) in female offspring at PND 50 with 10 mg/kg/day exposure.
Increased number of closed arm entries (p < 0.05) and time spent in closed arms (p < 0.05) in male offspring at PND 50 with 200 mg/kg/day exposure.
Increased time spent in closed arms in female offspring (p < 0.05) at PND 50 with 200 mg/kg/day exposure.
Increased escape latency on training days 2 (p < 0.001) and 3 (p < 0.05) in male offspring at PND 50 with 200 mg/kg/day exposure.
Reduced time spent in the target quadrant in male offspring during probe trial (p < 0.05) with 10 mg/kg/day and 50 mg/kg/day exposure.
Animal Model: ISA Brown laying hens (female, ~21 weeks of age, average weight 1.65 kg)
Dosage: 43.6 mg/kg body weight/day; 65.5 mg/kg body weight/day
Administration: p.o. via drinking water; daily; 7 days
Result: Reached concentrations in yolk ranging from 257-5358 μg/kg and in egg white ranging from 778-4737 μg/kg during treatment at 43.6 mg/kg/day dose.
Reached maximal concentrations of 5920 μg/kg in yolk and 4831 μg/kg in white on day 2 post-treatment at 43.6 mg/kg/day dose.
Had elimination half-life of 4.58 days in yolk and 8.04 days in white at 43.6 mg/kg/day dose.
Dropped below limit of detection (1.9 μg/kg) in yolk by day 16 post-treatment, and remained above limit of detection in white through day 37 post-treatment at 43.6 mg/kg/day dose.
Fell concentrations below 100 μg/kg in yolk between days 11-13 post-treatment, and in white between days 19-22 post-treatment at 43.6 mg/kg/day dose.
Reached concentrations in yolk ranging from 358-8101 μg/kg and in egg white ranging from 1025-6018 μg/kg during treatment at 65.5 mg/kg/day dose.
Reached maximal concentrations of 9453 μg/kg in yolk and 6050 μg/kg in white on day 2 post-treatment at 65.5 mg/kg/day dose.
Had elimination half-life of 5.37 days in yolk and 9.94 days in white at 65.5 mg/kg/day dose.
Dropped below limit of detection (1.9 μg/kg) in yolk by day 19 post-treatment, and remained above limit of detection in white through day 37 post-treatment at 65.5 mg/kg/day dose.
Fell concentrations below 100 μg/kg in yolk between days 11-13 post-treatment, and in white between days 19-22 post-treatment at 65.5 mg/kg/day dose.
Observed significant differences in concentrations between yolk and white during post-treatment period (p ≤ 0.05): for 43.6 mg/kg/day dose, higher concentrations were measured in white on days 7, 10, 13, and 16; for 65.5 mg/kg/day dose, higher concentrations were measured in white on days 1-19 (except day 4).
性状 固体
颜色 White to off-white

化学信息

分子量 302.29
分子式 C11H11N4NaO3S
CAS No. 38006-08-5
别名 磺胺间甲氧嘧啶钠盐

储存&溶解度

储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 175 mg/mL (578.91 mM; 超声助溶)

DMSO 中的溶解度 : 100 mg/mL (330.81 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO / H2O1 mM3.3081 mL16.5404 mL33.0808 mL82.7020 mL
5 mM0.6616 mL3.3081 mL6.6162 mL16.5404 mL
10 mM0.3308 mL1.6540 mL3.3081 mL8.2702 mL
15 mM0.2205 mL1.1027 mL2.2054 mL5.5135 mL
20 mM0.1654 mL0.8270 mL1.6540 mL4.1351 mL
25 mM0.1323 mL0.6616 mL1.3232 mL3.3081 mL
30 mM0.1103 mL0.5513 mL1.1027 mL2.7567 mL
40 mM0.0827 mL0.4135 mL0.8270 mL2.0676 mL
50 mM0.0662 mL0.3308 mL0.6616 mL1.6540 mL
60 mM0.0551 mL0.2757 mL0.5513 mL1.3784 mL
80 mM0.0414 mL0.2068 mL0.4135 mL1.0338 mL
100 mM0.0331 mL0.1654 mL0.3308 mL0.8270 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础